How did advisers react to the primary psychedelic remedy to go earlier than the Meals and Drug Administration? And did the American Society of Scientific Oncology assembly surpass expectations?
We talk about that and extra on this week’s episode of “The Readout LOUD.” STAT colleague Meghana Keshavan joins us to dissect Lykos Therapeutics’ assembly with an FDA advisory committee. We additionally talk about the most recent information within the well being and life sciences, together with tales from main biotech conferences.
To study extra about Lykos’ advisory committee assembly, go right here; for extra on the tumult at BIO, go right here; for a recap of ASCO, go right here; to learn the most recent on Novartis’ acquisition of MorphoSys, go right here. And you may join Adam’s new e-newsletter, Biotech Scorecard, right here.
Make sure to join “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
